ReviewInternational ophthalmology2025
Intracameral medications in cataract surgery.
Review in International ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo review the indications, dosages, and safety profiles of intracameral drugs used during cataract surgery.
methodsA narrative review was conducted, evaluating published clinical studies, review articles, and guidelines related to intracameral drug use in cataract surgery. The analysis focused on drugs commonly used for anesthesia, mydriasis, inflammation control, and intraoperative complication management. Special consideration was given to their utility in high-risk surgical scenarios, such as small pupils, intraoperative floppy iris syndrome, white or pediatric cataracts, and cases with zonular weakness.
resultsIntracameral drugs have proven beneficial in achieving effective anesthesia, maintaining pupil dilation, and controlling inflammation during cataract surgery. Their use is particularly advantageous in complex cases, including those with corneal opacity, posterior capsular rupture, or combined procedures like minimally invasive glaucoma surgery and premium IOL implantation. When prepared and administered properly, these agents contribute to safer and more efficient surgeries. However, improper preparation or dosing can lead to ocular toxicity, highlighting the importance of meticulous handling.
conclusionIntracameral drug administration is a valuable adjunct in cataract surgery, enabling surgeons to manage routine and complex cases more effectively. Understanding their appropriate use and potential risks is essential to maximize patient safety and surgical success.
Indexed as
Identifiers
40381121What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.